Javtor/biomedical-topic-categorization-validation

PMID int64 35.7M 36.4M	Title/Abstract stringlengths 22 8.78k	MeshTerms stringlengths 7 101	SemanticTypes stringlengths 4 64
36,328,424	bioinformat analysi molecular mechan qibaipingfei capsul regul chronic obstruct pulmonari diseas relat immun cell object investig mechan qibaipingfei capsul regul chronic obstruct pulmonari copd relat immun cell analyz singl cell transcriptom sequenc scrna seq data copd lung tissu pharmacolog qibaipingfei capsul method scrna seq data copd lung tissu download gene express omnibus geo use obtain copd relat immun cell differenti express rna primari activ molecular target gene qibaipingfei capsul retriev tradit chines medicin system pharmacolog databas analysi platform tcmsp activ molecul immun cell target gene network construct map target gene qibaipingfei capsul differenti express rna copd relat immun cell gene ontolog go kyoto encyclopedia gene genom kegg protein protein interact ppi administr analyz molecular mechan target gene result twelv activ molecul includ quercetin kaempferol formononetin qibaipingfei capsul target multipl copd relat immun cell like macrophag alveolar macrophag cell gene like pparg jun hmox hifa primarili collect pathway interleukin signal pathway nuclear factor b nf b signal pathway mitogen activ protein kinas mapk signal pathway conclus qibaipingfei capsul may target multipl immun cell interven inflamm immun relat pathway regul inflamm immun respons copd	D029424;D004365	T123;T047;T121
36,328,401	effect safeti tocilizumab patient system sclerosi propens score match control observ studi eustar cohort tocilizumab show trend improv skin fibrosi prevent progress lung fibrosi system sclerosi ssc randomis control clinic trial aim assess safeti effect tocilizumab real life set use european scleroderma trial research eustar databas	D011658;D012595	T047
36,328,400	risk pre eclampsia impact diseas activ antirheumat treatment women rheumatoid arthriti axial spondylarthr psoriat arthriti collabor match cohort studi sweden denmark explor risk pre eclampsia rheumatoid arthriti ra axial spondyloarthr axspa psoriat arthriti psa focus impact treatment diseas activ	D015535;D011225;D018501;D001172;D000089183	T121;T047;T046
36,328,399	immunogen safeti three dose sar cov vaccin strategi patient immun mediat inflammatori diseas immunosuppress therapi humor vaccin respons sar cov vaccin impair short last patient immun mediat inflammatori diseas imid follow two vaccin dose protect vulner patient sever covid diseas three dose primari vaccin strategi implement mani countri aim studi evalu humor respons safeti primari vaccin three dose patient imid	D000086382;D014765	T129;T047;T121;T067
36,328,395	pharmacokinet hydroxychloroquin paediatr lupus data novel direct famili clinic trial determin pharmacokinet pk exposur respons hydroxychloroquin hcq desethylhydroxychloroquin dhcq paediatr sle psle	D018501;D008180	T121;T047
36,328,394	matern socioeconom status infant feed practic under pathway child stunt cambodia structur path analysi use cross section popul data identifi investig complex pathway stunt among children age month determin mediat effect dietari divers continu breast feed associ socioeconom factor child stunt	D007227;D006130	T061;T040;T046
36,328,393	factor associ low medium household dietari divers compar high dietari divers among marginalis household rural bangladesh find suchana baselin survey studi aim identifi associ factor low medium household hh dietari divers dd compar high dd among marginalis household rural bangladesh	D005523;D004032	T081;T168
36,328,392	effect communic communiti immun covid vaccin hesit peopl ethnic divers background experiment vignett studi uk achiev high vaccin coverag vital effort curb impact covid pandem public health societi studi test whether communic social benefit communiti protect friend famili member versus overal societi affect vaccin intent percept among sampl enrich respond black ethnic minor background	D000086663;D000086382	T200;T047;T067
36,328,391	communic medic manag patient physician consult primari care particip observ studi explor communic medic manag annual consult primari care	D054539;D058005	T089;T058;T097
36,328,390	effect virtual realiti function mobil treadmil train children cerebr palsi singl blind two arm parallel group randomis clinic trial virtwalkcp project treadmil train virtual realiti investig children cerebr palsi howev studi assess effect combin treatment children function balanc activ project aim compar effect treadmil train without virtual realiti walk endur speed static dynam balanc gross motor function function independ qualiti life occup particip children spastic cerebr palsi age year classifi level ii iii gross motor function classif system	D002547;D000076142	T019;T047;T066
36,328,389	perceiv feasibl facilit barrier incorpor point care test sar cov emerg medic servic ambul servic staff survey base approach bodi work aim elicit ambul servic staff percept barrier facilit adopt clinic util incorpor rapid sar cov test ambul assess	D000086382;D004632	T061;T067;T093;T047;T058
36,328,388	studi protocol multicentr compar diagnost accuraci studi tool establish presenc sever peripher arteri diseas peopl diabet mellitus dm pad studi peripher arteri diseas pad key risk factor cardiovascular diseas foot ulcer lower limb amput peopl diabet earli diagnosi pad enabl optimis therapi manag risk diagnosi fundament though challeng context diabet although varieti diagnost bedsid test avail agreement accur routin clinic practiceth aim studi determin diagnost perform varieti test audibl waveform assess visual waveform assess ankl brachial pressur index abpi exercis abpi toe brachial pressur index tbpi diagnosi pad peopl diabet determin refer test ct angiographi cta magnet reson angiographi mra select centr also aim evalu perform new point care duplex ultrasound scan pad scan	D058729;D003920	T047
36,328,387	laparoscop excis superfici periton endometriosi help harm protocol doubl blind randomis placebo control three arm surgic trial placebo control surgic design recommend ascertain treatment effect elect surgeri genuin doubt effect surgeri elect surgeri pain unabl show effect beyond sham surgeri suggest contribut contextu factor howev natur contextu factor elect surgeri larg unexplor methodolog difficulti placebo control surgic trial impact abil estim effect surgic procedur includ overal lack test success blind absenc comparison surgeri control group dearth test neuropath painfor women periton endometriosi uncertainti regard pain reliev effect surgeri surgeri may put patient risk complic postsurg neuropath pain without guarante suffici pelvic pain relief plan placebo control trial aim examin effect surgeri pelvic pain widespread pain neuropath pain symptom women periton endometriosi test contribut contextu factor pain relief	D004715;D010535;D009437	T061;T184;T060;T191;T047
36,328,386	serum oestradiol level risk advers cardiovascular event associ gender affirm oestrogen therapi protocol systemat review meta analysi use gender affirm oestrogen therapi gaot integr part gender affirm transit process transgend women assign male birth identifi women gender divers individu howev use may present signific cardiovascular implic may influenc system oestradiol level therefor aim establish associ serum oestradiol level incid advers cardiovascular event individu use gaot	D002318	T047
36,328,385	integr clinic pharmacist workforc newli form primari care network qualit driven complex system analysi introduct new clinic pharmacist workforc via primari care network pcns recent nation polici develop nation health servic england studi elicit perspect peopl respons local implement nation polici packag attent local deliveri necessari understand contextu factor shape integr new clinic pharmaci workforc thus expect influenc futur role develop	D010595;D013222	T064;T097
36,328,384	patient percept conflict inform chronic medic prospect survey switzerland number patient chronic diseas subsequ visit various healthcar profession rise past decad expos patient potenti risk receiv conflict medic inform studi aim investig preval conflict inform medic perceiv chronic patient switzerland understand impact patient medic self manag navig healthcar system	D010595;D055118	T033;T055;T081;T097
36,328,383	best caseworst case protocol multisit randomis clinic trial scenario plan intervent patient kidney failur given burden treatment poor prognosi older adult kidney failur would benefit improv decis make palliat care clarifi goal address symptom reduc unwant procedur best caseworst case bcwc communic tool use scenario plan support patient decis make articl describ protocol multisit cluster randomis trial test effect train nephrologist use bcwc communic tool patient receipt palliat care qualiti life communic	D011788;D051437	T078;T047
36,328,382	diagnost accuraci blood test inflamm paediatr append systemat review meta analysi possibl childhood append common emerg present exact valu blood test debat studi sought determin diagnost accuraci four blood test white cell count wcc neutrophil count percentag c reactiv protein crp andor procalcitonin childhood append	D001064	T047
36,328,381	multimorbid pocket expenditur medicin china india use nation repres survey data china india studi examin distribut pattern multimorbid relat socioeconom status associ multimorbid pocket expenditur oop medicin socioeconom group	D005102;D000076322	T081;T078
36,328,378	metformin increas natur killer cell function head neck squamous cell carcinoma cxcl inhibit metformin slow tumor growth progress vitro combin chemoradiotherapi result high overal surviv patient head neck cancer squamous cell carcinoma hnscc phase clinic trial nct metformin also postul activ antitumor immun respons investig immunolog effect metformin natur killer nk natur killer cell includ result two phase open label studi patient hnscc treat metformin nct nct	D006258;D002294;D008687	T121;T191;T109
36,328,377	fraction rcc nivolumab plus ipilimumab advanc renal cell carcinoma progress immuno oncolog therapi role sequenc combin immuno oncolog io therapi follow progress first line io therapi well establish fast real time assess combin therapi immuno oncolog fraction program open label phase platform trial design evalu multipl io combin patient advanc renal cell carcinoma arcc progress prior io therapi describ result patient treat nivolumab plus ipilimumab enrol track report patient histolog confirm clear cell arcc karnofski perform status life expect month previous progress io anti program death pd anti program death ligand pd l anti cytotox lymphocyt antigen ctla therapi elig previous treatment anti ctla therapi plus anti pd pd l therapi preclud elig enrol nivolumab plus ipilimumab arm patient treat nivolumab mgkg plus ipilimumab mgkg everi week four dose follow nivolumab mg everi week year progress toxic protocol specifi discontinu primari outcom measur object respons rate orr durat respons dor progress free surviv pfs rate week secondari outcom safeti toler year overal surviv os tertiaryexploratori endpoint overal patient includ median follow month orr ci eight patient achiev partial respons stabl diseas achiev patient progress diseas median dor rang month pfs rate week median os ci reach month grade immun mediat advers event report seven patient treatment relat death report patient arcc treat nivolumab plus ipilimumab may deriv durabl clinic benefit progress previous io therapi includ heavili pretreat patient manag safeti profil consist previous publish safeti outcom outcom contribut knowledg optim sequenc io therapi patient arcc high unmet need	D000971;D002292;D007680	T061;T191
36,328,375	transit pediatr adult care type diabet mellitus longitudin analysi age transfer gap care adolesc young adult aya type diabet td risk suboptim glycem control high acut care util littl known optim age transfer peopl td adult care time gap complet pediatr care begin adult endocrinolog care	D003922;D060305	T047;T058
36,328,372	effect oral antimicrobi prophylaxi surgic site infect elect colorect surgeri multicentr randomis doubl blind placebo control trial investig whether oral antimicrobi prophylaxi adjunct intraven antibiot prophylaxi reduc surgic site infect elect colorect surgeri	D003107;D009950;D000890	T121;T091;T109
36,328,364	complet ophthalmoplegia diagnos tolosa hunt syndrom interv mri tolosa hunt syndrom rare caus pain ophthalmoplegia common present retro orbit pain eye motor nerv palsi often affect singl eye condit characteris idiopath process caus granulomat inflamm cavern sinus affect one multipl cranial nerv pass therein mechan under inflamm well understood patient observ respond steroid flare present uniqu case multidisciplinari team diagnos tolosa hunt syndrom despit non specif mri find cavern sinus day follow initi normal mri	D020333;D009886;D002426	T033;T184;T047;T030
36,328,362	infant loey dietz syndrom treat febril status epilepticus covid infect first report case febril status epilepticus focal seizur patient loey dietz syndrom review literatur loey dietz syndrom lds rare autosom domin multisystem disord caus mutat transform growth factor receptor mutat smad tgfb recent reportedld characteris triad arteri tortuos hypertelor bifid uvula cleft palat among cardiovascular craniofaci orthopaed manifest patient lds show clinic genet variabl signific risk reduc life expect due widespread arteri involv aortic root dilat aneurysm aggress vascular cours thus earli genet test warrant clinic sign histori suggest potenti catastroph disorderld predispos patient aortic aneurysm earli death due vascular malform neurolog emerg seizur febril status epilepticus reportedfebril status epilepticus common neurolog emerg childhood neurolog manifest covid paediatr popul well describ medic literatureto best knowledg first report case febril status epilepticus covid infect infant lds patient focal epileptiform activ eman left posterior hemispher evolv electrograph seizur video eeg patient heighten risk epilepsi futur occurr consist diagnosi focal epilepsi neurolog complic epilepsi status epilepticus patient lds never report beforea brief review literatur also given	D055947;D000086382;D013226	T047;T067
36,328,361	float mural thrombus ascend aorta caus multiorgan infarct man sudden onset left side subcost pain diagnos splenic infarct thoracoabdomin ct contrast enhanc also reveal mural thrombus thoracoabdomin aorta rais possibl aortic dissect electrocardiograph find normal transthorac echocardiographi detect thrombus heart antihypertens medic administ admiss anticoagul therapi start develop left renal infarct occlus superior mesenter arteri nevertheless subsequ sustain acut cerebr infarct transoesophag echocardiographi reveal abnorm float structur ascend aorta surgic remov final diagnos organis thrombus although caus multiorgan infarct cardiogen float mural thrombus also caus anticoagul therapi may necessari patient recur sever embol even aortic dissect complet rule	D001018;D013927;D013923;D009203;D006331;D000784	T047;T046
36,328,355	synthet klhl ligand valid cul klhl potent e ligas target protein degrad target protein degrad tpd risen promis therapeut modal leverag catalyt natur ubiquitin proteasom enzymat machineri tpd exhibit higher potenc elimin diseas caus target protein oncogen transcript factor may otherwis difficult abrog convent inhibitor howev challeng remain current near degrad engag cul crbn cul vhl e ligas target ubiquitin immedi efficaci evid narrow e ligas option make tpd vulner potenti drug resist addit e ligas show differenti tissu express intrins limit access vari type diseas relev target success tpd close associ abil e ligas effici polyubiquitin target interest long term outlook tpd drug develop depend whether e ligas cul crbn cul vhl access target interest overcom potenti caveat broad collect action e ligas requir design macrocycl degrad engag cul klhl target bet protein valid cul klhl e ligas system suitabl tpd work thus contribut expans usabl e ligas potenti drug develop	D044767;D048868	T123;T126;T116
36,328,060	optoacoust tone generat nanosecond laser puls cover entir human hear rang aim work generat defin tone cover human hear rang aqueous media later applic middl inner ear implant experi investig characterist singl laser puls puls train differ laser repetit rate nanosecond laser puls focus aqueous media small volum frequenc generat tone limit spectral properti singl acoust puls depend medium tone fundament frequenc khz generat use laser puls focus water replac water gel tone hz khz could produc generat tone low frequenc rang possibl laser puls train puls densiti modul puls pattern appli gel enabl generat tone hz khz consequ combin differ puls pattern differ frequenc rang allow generat optoacoust tone hz khz gel thus cover complet rang human hear optoacoust generat tone	D006309;D000162	T039;T070
36,328,059	novel weight auxiliari set match pursuit method glioma cerenkov luminesc tomographi reconstruct cerenkov luminesc tomographi clt promis three dimension imag technolog activ investig preclin studi howev ill posed invers problem clt reconstruct reconstruct perform still satisfactori broad biomed applic studi novel weight auxiliari set match pursuit wasmp method explor enhanc accuraci clt reconstruct numer simul vivo imag studi use tumor bear mice model conduct evalu perform wasmp method result experi prove wasmp method achiev superior reconstruct perform approach term posit accuraci shape recoveri demonstr atom select strategi propos studi posit effect improv accuraci atom propos wasmp improv accuraci clt reconstruct biomed applic	D041622;D005910	T060;T191
36,328,058	tail artifact remov three dimension optic coher tomographi angiographi common part extract method optic coher tomographi angiographi octa blood vessel tail artifact tail superfici vessel shadow under deep vascular imag make difficult reconstruct three dimension imag vessel structur provid much inform two dimension imag import develop method remov artifact letter introduc imag process techniqu base common part extract remov artifact help subtract oper erod oper method reconstruct imag vascular network extract common part adjac b scan octa imag vessel palm use sampl experiment demonstr techniqu imag see interest phenomenon end blood vessel close surfac skin point toward surfac	D041623;D016477	T060;T068
36,328,055	digniti termin ill confront loss digniti suffer end life act digniti orient way usual abstract idea digniti fundament strengthen digniti focus deficit orient way sens digniti threaten look concept digniti health care system done two angl first direct gaze abus violat digniti right becom outrag moreov gain collect experi digniti violat covid pandem continu experi second focus enhanc digniti dignifi digniti orient aspir peopl work health care system follow articl intent devot second view open possibl digniti strengthen care health care system draw substanti research intervent develop harvey chochinov research team canada articl offer overview theoret foundat food thought self reflect action aid practic applic	D000078682;D000086382	T067;T055;T054;T047;T041
36,328,053	peri oper anaphylaxi antiqu custom news toward culprit periop anaphylaxi occur surgic procedur recent pathophysiolog anaphylact reaction via mast cell relat g protein und complement activ pseudo allergi ad old ige mediat etiolog new culprit anaphylact reaction chlorhexidin gelatin hemostypticum blue surgic dye mark situs biphas anaphylact reaction kept mind meantim propofol use allow egg soybean allerg patient	D000707;D005512;D015742	T121;T047;T046;T109
36,328,042	elect surgeri system strengthen develop measur valid surgic prepared index across hospit countri lancet commiss global surgeri identifi surgeri anaesthesia indispens part holist health care system howev covid expos fragil plan surgic servic around world also neglect pandem recoveri plan studi aim develop valid novel index support local elect surgic system strengthen address grow backlog	D058873;D000086382	T047;T067
36,328,040	addit isatuximab lenalidomid bortezomib dexamethason induct therapi newli diagnos transplant elig patient multipl myeloma gmmg hd part open label multicentr randomis activ control phase trial anti cd monoclon antibodi consist shown increas efficaci ad standard care patient multipl myeloma aim assess efficaci isatuximab addit lenalidomid bortezomib dexamethason patient newli diagnos transplant elig multipl myeloma	D009101	T191
36,328,025	acceler integr china global develop innov anticanc drug aim polici review compar china overal synchron particip clinic trial innov anticanc drug usa eu japan south korea assess chang particip rate trend five region relev data top intern pharmaceut compani systemat collect trialtrov pharmaproject databas among trial new anticanc drug identifi china involv trial drug triall particip rate signific lower south korea trial drug japan trial drug eu trial drug usa trial drug p similar result found synchron particip rate defin proport drug trial highest develop stage intern test drug rang china usa china particip rate earli phase trial synchron trial even lower stark contrast usa earli phase trial synchron trial fastest grow annual rate particip trial observ china follow south korea japan chang detect usa eu polici review show chines particip clinic develop innov cancer drug intern pharmaceut compani increas past decad obvious gap persist comparison usa eu japan south korea especi synchron particip earli particip rate	D000970	T121;T109
36,328,024	explor link cancer polici cancer surviv comparison intern cancer benchmark partnership countri cancer polici differ might help explain intern variat cancer surviv empir evid scarc review cancer polici intern cancer benchmark partnership jurisdict seven countri exploratori analys link index cancer polici consist time monitor implement mechan surviv seven cancer subset ten jurisdict ten jurisdict structur place overse deliv cancer control polici publish least one major cancer plan cancer plan explicit budget implement mandat extern evalu cancer polici consist posit correl improv surviv time six seven cancer site jurisdict score highest polici consist larg improv surviv site analysi provid import first step systemat captur evalu inher complex polici process find help guid polici maker seek approach framework improv cancer servic ultim cancer outcom	D019985;D009369	T081;T191
36,328,023	progress remain challeng cancer control gulf cooper council cancer grow global health care problem especi resourc countri cancer preval gulf cooper council gcc countri project increas potenti lead major burden economi polici maker gcc countri invest develop nation cancer control strategi address current futur burden cancer differ initi polici prevent earli detect manag cancer strategi includ capac build health educ global partnership strengthen health care system aim review highlight status cancer control programm gcc countri describ achiev date identifi gap recommend lower burden cancer gulf region futur translat arab translat abstract see supplementari materi section	D003695;D009369	T058;T191;T093
36,327,988	manag cylindr batteri ingest present femal present emerg depart follow ingest unknown number cylindr batteri diagnosi abdomin x ray confirm presenc multipl batteri locat throughout abdomen treatment trial conserv manag pursu five aa batteri success pass per rectum serial x ray three week reveal major batteri fail pass decis made perform laparotomi cylindr batteri remov stomach small gastrotomi four batteri locat colon milk rectum remov via transan rout discuss use daili clinic exam week plain film abdomen conserv manag possibl small number batteri ingest make stomach howev potenti cylindr batteri result acut surgic emerg underestim	D005547	T020;T037;T072
36,327,987	associ shift work normal weight obes communiti dwell adult shift work associ obes metabol syndrom howev associ normal weight popul remain unclear studi aim investig whether shift work associ normal weight obes nwo	D057187;D000073577	T056;T057
36,327,985	updat preoper parathyroid local primari hyperparathyroid parathyroidectomi treatment choic primari hyperparathyroid clinic criteria met although bilater neck explor tradit standard method surgeri minim invas parathyroidectomi mip focus parathyroidectomi wide accept compar curat outcom success mip accur preoper local parathyroid lesion essenti howev consensus exist optim approach local current ultrasonographi technetium sestamibi singl photon emiss comput tomographycomput tomographi wide accept case howev exact local alway achiev especi case multiglandular diseas ectop gland recurr diseas normocalcem primari hyperparathyroid therefor new modal preoper local develop evalu positron emiss tomographycomput tomographi parathyroid venous sampl demonstr improv sensit accuraci anatom function inform obtain combin method approach advantag disadvantag local studi deliber chosen base patient clinic profil cost radiat exposur avail experienc expert review summar various method local hyperfunct parathyroid tissu primari hyperparathyroid	D049950;D010282	T047;T191
36,327,984	updat paget diseas bone paget diseas bone preval bone diseas character disorgan bone remodel howev compar uncommon east asian countri includ china japan korea exact caus still remain unknown genet suscept individu environment trigger paramyxovir infect like caus diseas increas osteoclast activ result increas bone resorpt attract osteoblast generat new bone matrix fast bone resorpt format lead develop disorgan bone tissu increas serum alkalin phosphatas uniqu radiograph lesion may serv diagnost indic common symptom includ bone pain bow long bone enlarg skull hear loss diagnosi frequent confirm radiograph nuclear scintigraphi bone bisphosphon zoledron acid pamidron effect treatment moreov biochem monitor superior symptom recurr indic articl discuss updat paget diseas bone clinic case	D010001;D001862	T047;T042
36,327,969	caplacizumab use ttp case unrespons convent therapi introduct thrombot thrombocytopen purpura ttp rare life threaten disord caus sever reduc activ adamt caus platelet adhes format small vessel platelet rich thrombi thrombocytopenia microangiopath haemolyt anaemia diagnosi year old femal present acut general petechi rash bruis fatigu blood reveal thrombocytopenia anaemia schistocyt plasmic score seven adamt lt treatment patient initi respond plasma exchang steroid thrombocytopenia recur day six treatment need addit immunosuppress drug caplacizumab conclus ttp case unrespons convent regimen repres challeng situat howev poor outcom could potenti avoid novel therapi like caplacizumab patient medic well toler platelet count normal two day introduct	D011697;D061905	T129;T047;T116
36,327,900	sympathet nervous system st centuri neuroimmun interact metabol homeostasi obes sympathet nervous system maintain metabol homeostasi orchestr activ organ pancrea liver white brown adipos tissu first render thoma willi contemporari techniqu visual trace function probe axon arbor within organ understand sympathet nervous system start grow beyond classic model present review outlin evolut find provid updat neuroanatom map sympathet innerv offer autonom framework neuroendocrin loop leptin action discuss role immun cell regul sympathet termin metabol highlight potenti anti obes therapeut approach emerg modern appreci sns neural network vis vis histor fear sympathomimet pharmacolog shift focus post pre synapt target final critic apprais field need go	D015213;D013564	T022;T023;T040
36,327,899	neuron regul b cell immun anticipatori immun postur brain may sens evalu modul interven oper immun system would otherwis function autonom defens pathogen antibodi mediat immun one arm adapt immun may achiev steril protect infect lymphoid organ dens innerv immun cell support antigen specif antibodi respons express receptor neurotransmitt glucocorticoid hormon subject collect regul neuroendocrin autonom nervous system emerg evid reveal brain spleen axi regul antigen specif b cell respons antibodi mediat immun articl provid synthesi studi pertin neuron regul b cell respons secondari lymphoid organ propos concept defens immun postur brain initi top reaction anticip potenti tissu injuri requir immun protect	D009490;D007107	T022
36,327,898	perivascular space role neuroinflamm uncontest perivascular space play critic role maintain homeostasi prime neuroinflamm howev despit centuri intens research perivascular space mani open question remain anatom compart surround blood vessel within cns goal comprehens review summar literatur perivascular space human neuroinflamm associ anim diseas model describ cell type take part morpholog function aspect perivascular space space visual base propos model cascad event occur neuroinflammatori patholog also discuss current knowledg gap limit avail evid improv understand perivascular space could advanc comprehens pathophysiolog neuroinflamm open new therapeut window neuroinflammatori diseas multipl sclerosi	D008279;D000090862	T060;T059;T033;T170;T047
36,327,897	microgli efferocytosi dive alzheim diseas gene pool genom wide associ studi function genom studi link specif cell type gene pathway alzheim diseas ad risk particular ad risk allel primarili affect abund structur thus activ gene express macrophag strong implic microglia brain resid macrophag etiolog ad gene converg pathway endocytosisphagocytosi cholesterol metabol immun respons critic role core macrophag function efferocytosi review pathway highlight relev gene identifi latest ad genet genom studi describ may contribut ad pathogenesi investig function impact ad associ variant gene microglia essenti elucid diseas risk mechan develop effect therapeut approach	D017628;D000544	T047;T025;T048
36,327,896	cns mononuclear phagocyt system health diseas cns resid macrophag includ parenchym microglia border associ macrophag bam contribut neuron develop health vascular tissu integr steadi state border patrol mononuclear phagocyt dendrit cell monocyt confer import immun function cns protect pathogen threat includ aberr cell growth brain malign even though learn much contribut lymphocyt cns patholog better understand differenti role tissu resid invad phagocyt slowli emerg perspect propos cns neuroinflammatori diseas tissu resid macrophag trms contribut clear debri resolut inflamm wherea blood born phagocyt driver immunopatholog discuss remain challeng resolv special mononuclear phagocyt popul drive suppress immun effector function therebi potenti dictat outcom autoimmun brain cancer	D012157;D001932	T022;T191
36,327,895	microglia state nomenclatur field crossroad microgli research advanc consider recent decad yet constrain roll seri dichotomi rest versus activ versus dualist classif good bad microglia inconsist wide repertoir microgli state function develop plastic age diseas elucid recent year new design continu aris attempt describ differ microgli state notabl defin use transcriptom proteom may easili lead mislead although unintent coupl categori function address issu assembl group multidisciplinari expert discuss current understand microgli state dynam concept import address microgli function provid conceptu framework recommend use microgli nomenclatur research review editor serv foundat futur white paper	D017628	T025
36,327,894	advanc vitro model microglia action central nervous system cns microglia carri multipl task relat brain develop mainten brain homeostasi function cns recent advanc vitro model system allow us perform detail specif analys microgli function cns develop human pluripot stem cell hpscs base cell cultur method particular advanc brain organoid model offer better platform dissect microgli function various context despit improv method still definit restrict understand drawback benefit ensur proper use primer review current develop regard vitro microgli product character use address fundament question microgli function healthi diseas state discuss potenti futur improv particular emphasi brain organoid model	D017628;D039904	T025
36,327,893	immunocept defin brain regul immun emerg understand homeostat neuroimmun interact requir develop relev terminolog neuroview koren roll defin immunocept brain bidirect monitor control immun propos physiolog trace store immun relat inform immunengram distribut brain memori cell resid peripher tissu	D001921;D015213	T022;T023;T040
36,327,892	jonathan kipni interview neuron joni kipni discuss format academ year subsequ discoveri mening lymphat enthusiast prospect therapeut develop neuroimmunolog aris focus brain border	D008208;D008578	T022;T023
36,327,891	gloria choi interview neuron gloria choi give us overview work character neural circuit behavior affect immun challeng various context also learn uniqu perspect marri two disciplin neurosci immunolog	D000486;D009488;D009420	T022;T091
36,327,890	larri steinman larri steinman divid time neurolog clinic lab team help develop first antibodi therapi multipl sclerosi interview neuron talk famili upbring team strategi princip investig long trajectori translat medicin	D009103;D009462	T047;T091
36,327,889	frauk zipp frauk zipp clinician scientist expert multipl sclerosi neurolog disord interview neuron talk earli work neuroimmunolog lab research advanc understand interplay immun nervous system health diseas	D009103;D009422	T047
36,327,888	neuro immun interact spectacular forest special issu neuron present seri opinion review neuro immun interact recent insight profound nervous immun system affect bolster tran disciplinari collabor revolution neurosci immunolog like forest ecosystem organ thrive wither depend balanc compon highlight special issu small sampl ever grow list diseas influenc dysfunct neuro immun crosstalk rang multipl sclerosi brain cancer long covid alzheim	D000086382	T047;T067
36,327,641	preval oncogen human papillomavirus pregnant adolesc associ colpocytolog chang risk factor obstetr outcom author aim carri investig impact cervic oncogen human papillomavirus hpv detect pregnant adolesc clarifi preval risk factor consid import lack data topic brazil	D052685;D030361;D002583	T005;T191;T047
36,327,640	supplement l carnitin septic shock patient systemat review meta analysi sepsi septic shock sever difficult treat condit high lethal interest identifi new adjunct therapi effect reduc mortal context l carnitin investig trial potenti benefici drug therefor aim systemat review assess clinic evid support use l carnitin septic shock patient reduc risk mortal object review evalu effect l carnitin compar placebo usual care uc mortal rate hospit adult septic shock patient	D012772;D018805	T047;T046
36,327,639	variabl isokinet ankl strength differ healthi older men women elder weak lower limb muscl impair function task perform	D000842;D000843	T029;T030
36,327,584	contribut filtrat photocatalysi dom remov foul mechan situ uv led photocatalyt ceram membran process use ceram membran ultraviolet light emit diod uv led advanc applic photocatalyt membran water treatment systemat evalu contribut filtrat photocatalysi dissolv organ matter dom remov foul mechan situ uv led photocatalyt ceram membran filtrat result show physic reject primarili led remov kda molecul photocatalysi increas remov kda molecul caus small size microbi humic like protein like materi permeat situ uv led photocatalysi excel effect membran foul mitig regardless dom sourc domin foul mechan chang partial blockag gel layer format increas ca concentr chang uv treatment correl analysi reveal remov kda molecul contribut mitig revers irrevers foul resist small molecul major caus irrevers foul resist remov kda terrestri humic acid like contribut pore blockag mechan synthet water remov kda protein like materi close correl pore blockag mechan real water trihalomethan thms haloacet acid haa format potenti fp signific reduc photocatalyt ceram membran process precursor nitrogen disinfect product n dbps high toxic remov filtrat photocatalysi deserv attent membran reject made higher contribut better dbpfp control photocatalysi studi provid novel insight impact uv led dom remov dbpfp control foul mitig promot develop photocatalyt ceram membran filtrat	D008567;D018508	T074;T052;T057
36,327,550	effect age limb centr pressur coordin stand balanc evid reactiv control challeng among older adult interlimb tempor synchroni spatial symmetri centr pressur cop displac may vital contributor stand balanc control previous work among stroke survivor low frequenc cop displac hz contrast attribut correct balanc respons intern perturb present studi extend work explor age relat alter stabil control process stand balanc combin cop displac limb cop net addit individu limb cop timeseri calcul synchron forc platform data obtain younger adult older adult trial quiet stand discret wavelet transform use decompos anteroposterior mediolater cop net addit individu limb timeseri low frequenc high frequenc bandwidth root mean squar rms amplitud high low frequenc cop net displac calcul cross correl coeffici use assess extent limb tempor synchron ratio individu limb rms amplitud use assess limb spatial symmetri within high low frequenc bandwidth observ greater high frequenc anteroposterior cop net displac among older adult without age relat differ lower frequenc bandwidth mediolater direct older adult exhibit greater high frequenc anteroposterior limb synchron without age relat differ low frequenc bandwidth among spatial symmetri variabl present age relat alter cop net could repres conserv strategi ensur stabil wherebi age relat challeng stabil mainten stand offset greater demand stabil control increas high frequenc limb tempor synchron among older adult may suggest loss adapt balanc correct respons stand	D011187;D020521	T033;T047
36,327,460	dynam interplay thionin dna carbon ion irradi real time first principl studi understand interact deoxyribonucl acid dna photosensit ion irradi benefit develop aptasensor dna biosensor cancer diagnosi use real time time depend densiti function theori simul high energi c ion pass dna poli dg poli dc sequenc embed thionin diamino phenothiazinium th compar electron stop power esp evolut structur charg absorpt spectrum th insert lead increas space charg densiti larger electron de excit larger esp speed correspond maximum esp almost c ion pass th dna structur th slight chang still exist noncoval interact th dna absorpt coeffici depend electron occupi state th ion pass result indic low radiat dose th still dna detector although respons wavelength intens slight chang provid theoret refer improv possibl applic phenothiazin dye dna biosensor ion irradi	D010640;D015374	T121;T059;T075;T109
36,327,447	practic strategi health equiti research enhanc analyt rigor generat meaning insight qualit data research public health practition increas need leverag divers methodolog approach health equiti research lead innov assess health inequ develop intervent decreas health inequ one well suit approach use robust qualit method alon combin quantit method health equiti research employ qualit method studi design addit guidanc need conduct robust rigor qualit data analys share step analyt strategi health equiti research practition particular limit train qualit data analysi use effect execut qualit analysi inform health equiti driven effort strategi guid less experienc qualit methodolog employ pragmat approach analysi sound reason produc meaning insight use inform effort advanc health equiti communiti greatest need	D000069576	T080
36,327,444	long term clinic clerkship improv medic student attitud toward team collabor examin relat factor associ medic student attitud toward team collabor	D002982;D013337	T065;T097
36,327,438	inflammatori bowel diseas associ colorect cancer epidemiolog outcom english popul base studi patient inflammatori bowel diseas ibd colon increas risk colorect cancer crc studi investig epidemiolog ibd crc outcom	D003093;D015179;D015212;D003424;D002761	T047;T191
36,327,437	longitudin associ risk factor hepatocellular carcinoma patient cure hepat c virus infect limit data effect evolut risk factor hepatocellular carcinoma hcc patient virolog cure hepat c virus hcv infect	D006528;D008113;D019698;D006526	T047;T191
36,327,436	random dose find proof concept studi berberin ursodeoxychol patient primari scleros cholang primari scleros cholang psc fibroinflammatori diseas bile duct lead cirrhosi hepat decompens approv pharmaceut therapi psc berberin ursodeoxychol htd ionic salt berberin ursodeoxychol acid pleiotrop mechan action	D015209;D001599	T121;T047;T109
36,327,435	berberin ursodeoxychol treatment primari scleros cholang search elus pharmacolog holi grail need continu effect pharmacolog treatment primari scleros cholang psc remain elus ursodeoxychol acid udca known improv liver biochemistri specif serum alkalin phosphatas patient psc shown favour alter natur histori similar mani immunomodulatori medic studi treatment psc none demonstr unequivoc benefit issu journal pilot studi ursodeoxychol berberin salt vs placebo report although improv serum alkalin phosphatas report without control arm udca monotherapi possibl determin whether studi drug benefici udca studi psc therapeut arena need	D015209;D001599	T121;T047;T109
36,327,434	gastroesophag reflux diseas great screen criterion time move strategi control burden esophag adenocarcinoma gastroesophag reflux diseas gerd key pathogenesi barrett esophagus esophag adenocarcinoma eac endoscop screen select individu gerd symptom barrett esophagus eac recommend great major patient eac never undergon prior screen despit million esophagogastroduodenoscopi egd perform annual unit state among individu gerd symptom like due conflat among provid regard diagnost egd refractori symptom screen egd altern approach need de emphas gerd avoid confus increas uptak appropri screen	D001471;D004938;D005764;D000230	T047;T191
36,327,433	continu medic educ question novemb articl titl longitudin associ risk factor hepatocellular carcinoma patient cure hepat c virus infect	D008113;D006528;D006526	T047;T191
36,327,432	continu medic educ question novemb articl titl qualiti indic capsul endoscopi deep enteroscopi	D004502;D053704	T065;T060
36,327,419	preval metal level refer valu municip affect collaps mine tail dam brumadinho health project describ preval level arsenic cadmium mercuri lead manganes refer valu rv popul brumadinho ruptur mine tail dam verifi factor associ level	D002104;D008628	T131;T196
36,327,418	laboratori profil mine dam breach brumadinho health project result evalu chang select laboratori test popul includ brumadinho health project accord exposur dam failur	D002097	T129;T116
36,327,417	use psychotrop drug popul area affect tail dam ruptur brumadinho health project describ consumpt psychotrop drug adult popul resid brumadinho mina gerai vale dam collaps occur	D014151	T121;T039
36,327,416	preval psychiatr symptom associ factor adult popul area affect tail dam ruptur brumadinho health project examin preval psychiatr symptom associ factor adult popul brumadinho mg dam collaps	D013313	T048
36,327,415	factor associ paid work dam failur brumadinho health project analyz factor associ paid work dam failur base geograph strata among men women resid brumadinho mina gerai	D004651	T033;T098;T080
36,327,414	chronic respiratori diseas respiratori symptom mine dam ruptur brumadinho health project identifi factor associ asthma chronic obstruct pulmonari diseas copd respiratori symptom brumadinho state mina gerai brazil dam ruptur	D029424;D001249	T047
36,327,413	food consumpt brumadinho health project particip analyz food consumpt pattern resid brumadinho mina gerai brazil accord sociodemograph characterist neighborhood area resid	D014675;D005638	T168;T002
36,327,412	brumadinho health project food nutrit insecur versus socioeconom status dimens food system dam ruptur describ situat food insecur famili accord socioeconom characterist dimens food system brumadinho state mina gerai brazil dam ruptur crrego feijo mine	D005523;D009752	T081;T033
36,327,411	sociodemograph residenti factor associ multimorb result brumadinho health project evalu preval multimorbid sociodemograph residenti factor associ condit among adult live brumadinho mina gerai	D000076322	T078
36,327,410	healthcar access util qualiti disast result brumadinho health project januari dam crrego feijo mine suffer catastroph failur kill peopl caus extens damag unknown exposur disast might affect healthcar util	D001786;D004190	T067;T109
36,327,409	mine dam disast system risk brazil record two serious disast involv mine dam st centuri purpos articl offer understand disast system risk involv global nation process relat social determin materi complex system dam distribut throughout countri intrins risk occur result set impact potenti damag immedi effect combin secondari tertiari impact trigger chain reaction promot risk factor heterogen complex occurr approach event point view system risk allow broader understand singular disast multipl exposur risk diseas process well structur characterist social polit process dynam econom factor reproduc multipl territori common pattern disast effect conclud promot popul health sustain territori guid organ product process opposit extern human environment social cost mine disast	D004190	T067
36,327,408	protocol longitudin studi child health brumadinho mg bruminha project present research protocol describ preliminari result bruminha project	D000067576	T078;T058
36,327,407	brumadinho health project methodolog aspect epidemiolog profil particip cohort baselin present methodolog aspect brumadinho health project describ epidemiolog profil particip baselin cohort	D015331	T062;T081
36,327,405	nlrp inflammasom inhibitor mcc reduc damag pancreat intestin barrier function mice acut pancreat abnorm activ nod like receptor protein nlrp inflammasom lead occurr progress acut pancreat studi investig protect effect mcc pancreat mice	D058847;D000071199;D010195	T123;T047;T046;T116
36,327,404	jatrorrhizin reduc myocardi infarct induc apoptosi fibrosi inhibit p tgf smad pathway mice explor mechan jatrorrhizin apoptosi fibrosi induc myocardi infarct mi anim model	D009203;D053773	T123;T047;T121;T116
36,327,403	tanshinon iia amelior myocardi ischemiareperfus injuri rat regul nlrp inflammasom activ th cell differenti tanshinon iia well known lipophil activ constitu refin tradit chines medicin danshen previous demonstr possess various biolog properti includ anti inflammatori antioxid promot angiogenesi effect howev mechan tanshinon iia myocardi ischemia reperfus injuri miri remain unclear studi investig effect tanshinon iia miri	D015428	T046
36,327,401	comprehens model implement agricultur land level consolid plan abu fazel region ahvaz shown land fragment negat impact effici farm therefor expert recommend land consolid process logic workabl solut solv problem complic caus land fragment land level consolid process land reform chang construct agricultur land lead rural develop reform farm manag howev singl plan appli differ region even though might countri henc vital investig multipl factor certain region devis perfect consolid plan present studi survey exploratori research conduct provid comprehens model implement plan level consolid agricultur land abu fazel region ahvaz iran research appli field research use librari field method collect requir data studi popul abu fazel northeast ahvaz zargan region result studi show cultur social econom polici make educ agricultur manageri factor effect particip farmer level consolid agricultur land studi area p also strong posit relationship factor farmer particip level consolid agricultur land p among factor observ polici main factor policymak play effect role land consolid macro develop one hand agricultur rural develop accur assess interact effect land consolid relat factor along effect process evolut agronom system	D000383;D003247	T078;T090;T069;T081;T064
36,327,400	temperatur variat nest paleosuchus palpebrosus crocodylia alligatorida near southern edg speci rang brazil monitor temperatur seven paleosuchus palpebrosus nest found bank stream surround brazilian pantan near southern limit speci distribut mean temperatur nest day incub presum period sex determin vari c nest temperatur c higher air temperatur presum due metabol heat decay materi within nest air temperatur explain varianc egg chamber temperatur estim incub period nest egg hatch day mean sd day though probabl slight overestim egg may hatch period inspect nest signific relationship mean temperatur incub period r p	D000489	T014
36,327,399	method applic salicyl acid attenu salt stress cherri tomato salt stress caus excess salt present irrig water one biggest barrier agricultur product especi semi arid region thus use substanc salicyl acid minim deleteri effect salin plant altern ensur satisfactori product context object studi evalu effect differ method applic salicyl acid growth product water use effici cherri tomato plant salt stress studi conduct greenhous use entisol soil sandi loam textur treatment distribut complet random design factori arrang correspond two level electr conduct irrig water ecw ds four method applic salicyl acid control without applic sa via spray via irrig via spray irrig five replic one plant per plot salicyl acid concentr use differ method mm applic salicyl acid via foliar spray increas growth product water use effici cherri tomato plant salt stress induc electr conduct ds attenu foliar applic salicyl acid use water ds associ applic salicyl acid via irrig water intensifi advers effect salin cherri tomato plant	D018551	T168;T002
36,327,398	use aerob treadmil exercis nerv regener sciatic nerv injuri spontan hypertens rat various postop protocol propos improv outcom acceler nerv regener recent use physic exercis post surgic neurorraphi procedur shown good result start earli experiment investig hypothesi post oper exercis speed result improv clinic morpholog paramet	D009416;D059348;D020426;D010805	T042;T037;T043;T047;T038
36,327,397	anatom descript extratempor facial nerv high definit system microsurg studi rat describ microsurg anatom aspect extratempor facial nerv wistar rat high definit video system	D005154;D004210	T061;T023
36,327,396	incision hernia repair rat descript sublay techniqu videomagnif system describ techniqu sublay correct incision hernia wistar rat videomagnif system	D000069290;D006555	T046;T190
36,327,395	outbreak toxoplasmosi associ muscular lesion finish pig caus atyp toxoplasma gondii genotyp toxoplasma gondii infect usual asymptomat pig acut clinic diseas rare host studi aim determin patholog molecular aspect outbreak fatal system toxoplasmosi finish pig brazil outbreak occur commerci finish pig farm state santa catarina southern brazil farm pig mortal rate outbreak pig fever anorexia apathi locomotor deficit seven pig necropsi gross find includ multifoc coalesc pale area skelet muscl lymphadenomegali hepatosplenomegali non colaps lung histolog find includ granulomat lymphaden hepat spleniti necrot myositi lymphoplasmacyt interstiti pneumonia lung liver lesion occasion accompani gondii parasit structur posit immunolabel gondii tachyzoit encyst bradyzoit detect examin pig pcr rflp marker microsatellit analysi marker identifi non archetyp genotyp pig first report system toxoplasmosi pig muscl lesion addit show divers diseas caus gondii genotyp circul anim brazil	D014122;D014124;D013553	T047;T204
36,327,393	auditori process intervent program school age children develop content valid studi aim develop content valid auditori process intervent program school age european portugues speak children auditori process disord	D001307;D001308	T041;T048
36,327,391	cdc clinic practic guidelin prescrib opioid pain unit state guidelin provid recommend clinician provid pain care includ prescrib opioid outpati age year updat cdc guidelin prescrib opioid chronic pain unit state mmwr recomm rep rr includ recommend manag acut durat month pain recommend appli pain relat sickl cell diseas cancer patient receiv palliat end life care guidelin address follow four area determin whether initi opioid pain select opioid determin opioid dosag decid durat initi opioid prescript conduct follow assess risk address potenti harm opioid use cdc develop guidelin use grade recommend assess develop evalu grade framework recommend base systemat review scientif evid reflect consider benefit harm patient clinician valu prefer resourc alloc cdc obtain input board scientif counselor nation center injuri prevent control feder charter advisori committe public peer review cdc recommend person pain receiv appropri pain treatment care consider benefit risk treatment option context patient circumst recommend appli inflex standard care across patient popul clinic practic guidelin intend improv communic clinician patient benefit risk pain treatment includ opioid therapi improv effect safeti pain treatment mitig pain improv function qualiti life patient pain reduc risk associ opioid pain therapi includ opioid use disord overdos death	D059350;D009293	T184;T047;T048
36,327,381	preval distribut refract error among member us arm forc us coast guard calendar year estim preval myopia hyperopia astigmat activ compon us arm forc us coast guard respect preval spectacl correct activ compon us arm forc includ singl vision distanc multifoc eg bifoc singl vision read spectacl comparison preval spectacl correct us coast guard addit among us arm forc servic member receiv spectacl correct distanc vision servic member reserv compon militari academi cadet nation guard signific myopic near sighted activ compon coast guard p within activ compon air forc myopic marin corp follow close militari branch signific differ p signific myopic navi armi p navi myopic armi p us coast guard signific less myopic militari branch p	D008889;D012030;D006956;D001251;D009216	T047;T097
36,327,377	musculoskelet injuri us air forc special warfar train assess select fiscal year incept special warfar train wing fiscal year male enlist candid attempt least assess select self elimin ie quit candid averag year age candid first attempt individu experienc musculoskelet msk injuri among injuri frequent type nonspecif n common anatom region injuri lower extrem n includ multivari model older age slower run time initi fit test prior nonspecif injuri associ injuri specif lower extrem msk injuri	D008889;D009140	T047;T097
36,327,353	complex disloc metacarpophalang joint index finger child case report author report complex metacarpophalang joint disloc year old adolesc boy multipl fail close reduct manipul unsuccess open procedur patient underw anoth surgic procedur volar approach joint reduc along volar plate repair function outcom year follow excel	D004204;D019651	T061;T037
36,327,350	reifi racism medicin master health racial scienc slaveri us medic school christoph e willoughbi univers north carolina press pp fals belief racial differ long histori physician train program	D063505;D063947	T054
36,327,349	solv brain circuit function dysfunct comput model optogenet fmri construct model brain function enabl understand whole brain circuit mechan under neurolog diseas use predict outcom therapeut intervent patholog neurolog diseas observ spatial spread mechan associ circuit brain function review discuss approach use date futur direct explor answer question combin optogenet function magnet reson imag fmri comput model cell type specif larg scale brain circuit function dysfunct begin quantit parameter envis develop pave path futur therapeut develop base system engin approach aim direct restor brain function	D062308;D009422	T063;T047

36,328,424

bioinformat analysi molecular mechan qibaipingfei capsul regul chronic obstruct pulmonari diseas relat immun cell object investig mechan qibaipingfei capsul regul chronic obstruct pulmonari copd relat immun cell analyz singl cell transcriptom sequenc scrna seq data copd lung tissu pharmacolog qibaipingfei capsul method scrna seq data copd lung tissu download gene express omnibus geo use obtain copd relat immun cell differenti express rna primari activ molecular target gene qibaipingfei capsul retriev tradit chines medicin system pharmacolog databas analysi platform tcmsp activ molecul immun cell target gene network construct map target gene qibaipingfei capsul differenti express rna copd relat immun cell gene ontolog go kyoto encyclopedia gene genom kegg protein protein interact ppi administr analyz molecular mechan target gene result twelv activ molecul includ quercetin kaempferol formononetin qibaipingfei capsul target multipl copd relat immun cell like macrophag alveolar macrophag cell gene like pparg jun hmox hifa primarili collect pathway interleukin signal pathway nuclear factor b nf b signal pathway mitogen activ protein kinas mapk signal pathway conclus qibaipingfei capsul may target multipl immun cell interven inflamm immun relat pathway regul inflamm immun respons copd

D029424;D004365

T123;T047;T121

36,328,401

effect safeti tocilizumab patient system sclerosi propens score match control observ studi eustar cohort tocilizumab show trend improv skin fibrosi prevent progress lung fibrosi system sclerosi ssc randomis control clinic trial aim assess safeti effect tocilizumab real life set use european scleroderma trial research eustar databas

D011658;D012595

T047

36,328,400

risk pre eclampsia impact diseas activ antirheumat treatment women rheumatoid arthriti axial spondylarthr psoriat arthriti collabor match cohort studi sweden denmark explor risk pre eclampsia rheumatoid arthriti ra axial spondyloarthr axspa psoriat arthriti psa focus impact treatment diseas activ

D015535;D011225;D018501;D001172;D000089183

T121;T047;T046

36,328,399

immunogen safeti three dose sar cov vaccin strategi patient immun mediat inflammatori diseas immunosuppress therapi humor vaccin respons sar cov vaccin impair short last patient immun mediat inflammatori diseas imid follow two vaccin dose protect vulner patient sever covid diseas three dose primari vaccin strategi implement mani countri aim studi evalu humor respons safeti primari vaccin three dose patient imid

D000086382;D014765

T129;T047;T121;T067

36,328,395

pharmacokinet hydroxychloroquin paediatr lupus data novel direct famili clinic trial determin pharmacokinet pk exposur respons hydroxychloroquin hcq desethylhydroxychloroquin dhcq paediatr sle psle

D018501;D008180

T121;T047

36,328,394

matern socioeconom status infant feed practic under pathway child stunt cambodia structur path analysi use cross section popul data identifi investig complex pathway stunt among children age month determin mediat effect dietari divers continu breast feed associ socioeconom factor child stunt

D007227;D006130

T061;T040;T046

36,328,393

factor associ low medium household dietari divers compar high dietari divers among marginalis household rural bangladesh find suchana baselin survey studi aim identifi associ factor low medium household hh dietari divers dd compar high dd among marginalis household rural bangladesh

D005523;D004032

T081;T168

36,328,392

effect communic communiti immun covid vaccin hesit peopl ethnic divers background experiment vignett studi uk achiev high vaccin coverag vital effort curb impact covid pandem public health societi studi test whether communic social benefit communiti protect friend famili member versus overal societi affect vaccin intent percept among sampl enrich respond black ethnic minor background

D000086663;D000086382

T200;T047;T067

36,328,391

communic medic manag patient physician consult primari care particip observ studi explor communic medic manag annual consult primari care

D054539;D058005

T089;T058;T097

36,328,390

effect virtual realiti function mobil treadmil train children cerebr palsi singl blind two arm parallel group randomis clinic trial virtwalkcp project treadmil train virtual realiti investig children cerebr palsi howev studi assess effect combin treatment children function balanc activ project aim compar effect treadmil train without virtual realiti walk endur speed static dynam balanc gross motor function function independ qualiti life occup particip children spastic cerebr palsi age year classifi level ii iii gross motor function classif system

D002547;D000076142

T019;T047;T066

36,328,389

perceiv feasibl facilit barrier incorpor point care test sar cov emerg medic servic ambul servic staff survey base approach bodi work aim elicit ambul servic staff percept barrier facilit adopt clinic util incorpor rapid sar cov test ambul assess

D000086382;D004632

T061;T067;T093;T047;T058

36,328,388

studi protocol multicentr compar diagnost accuraci studi tool establish presenc sever peripher arteri diseas peopl diabet mellitus dm pad studi peripher arteri diseas pad key risk factor cardiovascular diseas foot ulcer lower limb amput peopl diabet earli diagnosi pad enabl optimis therapi manag risk diagnosi fundament though challeng context diabet although varieti diagnost bedsid test avail agreement accur routin clinic practiceth aim studi determin diagnost perform varieti test audibl waveform assess visual waveform assess ankl brachial pressur index abpi exercis abpi toe brachial pressur index tbpi diagnosi pad peopl diabet determin refer test ct angiographi cta magnet reson angiographi mra select centr also aim evalu perform new point care duplex ultrasound scan pad scan

D058729;D003920

T047

36,328,387

laparoscop excis superfici periton endometriosi help harm protocol doubl blind randomis placebo control three arm surgic trial placebo control surgic design recommend ascertain treatment effect elect surgeri genuin doubt effect surgeri elect surgeri pain unabl show effect beyond sham surgeri suggest contribut contextu factor howev natur contextu factor elect surgeri larg unexplor methodolog difficulti placebo control surgic trial impact abil estim effect surgic procedur includ overal lack test success blind absenc comparison surgeri control group dearth test neuropath painfor women periton endometriosi uncertainti regard pain reliev effect surgeri surgeri may put patient risk complic postsurg neuropath pain without guarante suffici pelvic pain relief plan placebo control trial aim examin effect surgeri pelvic pain widespread pain neuropath pain symptom women periton endometriosi test contribut contextu factor pain relief

D004715;D010535;D009437

T061;T184;T060;T191;T047

36,328,386

serum oestradiol level risk advers cardiovascular event associ gender affirm oestrogen therapi protocol systemat review meta analysi use gender affirm oestrogen therapi gaot integr part gender affirm transit process transgend women assign male birth identifi women gender divers individu howev use may present signific cardiovascular implic may influenc system oestradiol level therefor aim establish associ serum oestradiol level incid advers cardiovascular event individu use gaot

D002318

T047

36,328,385

integr clinic pharmacist workforc newli form primari care network qualit driven complex system analysi introduct new clinic pharmacist workforc via primari care network pcns recent nation polici develop nation health servic england studi elicit perspect peopl respons local implement nation polici packag attent local deliveri necessari understand contextu factor shape integr new clinic pharmaci workforc thus expect influenc futur role develop

D010595;D013222

T064;T097

36,328,384

patient percept conflict inform chronic medic prospect survey switzerland number patient chronic diseas subsequ visit various healthcar profession rise past decad expos patient potenti risk receiv conflict medic inform studi aim investig preval conflict inform medic perceiv chronic patient switzerland understand impact patient medic self manag navig healthcar system

D010595;D055118

T033;T055;T081;T097

36,328,383

best caseworst case protocol multisit randomis clinic trial scenario plan intervent patient kidney failur given burden treatment poor prognosi older adult kidney failur would benefit improv decis make palliat care clarifi goal address symptom reduc unwant procedur best caseworst case bcwc communic tool use scenario plan support patient decis make articl describ protocol multisit cluster randomis trial test effect train nephrologist use bcwc communic tool patient receipt palliat care qualiti life communic

D011788;D051437

T078;T047

36,328,382

diagnost accuraci blood test inflamm paediatr append systemat review meta analysi possibl childhood append common emerg present exact valu blood test debat studi sought determin diagnost accuraci four blood test white cell count wcc neutrophil count percentag c reactiv protein crp andor procalcitonin childhood append

D001064

T047

36,328,381

multimorbid pocket expenditur medicin china india use nation repres survey data china india studi examin distribut pattern multimorbid relat socioeconom status associ multimorbid pocket expenditur oop medicin socioeconom group

D005102;D000076322

T081;T078

36,328,378

metformin increas natur killer cell function head neck squamous cell carcinoma cxcl inhibit metformin slow tumor growth progress vitro combin chemoradiotherapi result high overal surviv patient head neck cancer squamous cell carcinoma hnscc phase clinic trial nct metformin also postul activ antitumor immun respons investig immunolog effect metformin natur killer nk natur killer cell includ result two phase open label studi patient hnscc treat metformin nct nct

D006258;D002294;D008687

T121;T191;T109

36,328,377

fraction rcc nivolumab plus ipilimumab advanc renal cell carcinoma progress immuno oncolog therapi role sequenc combin immuno oncolog io therapi follow progress first line io therapi well establish fast real time assess combin therapi immuno oncolog fraction program open label phase platform trial design evalu multipl io combin patient advanc renal cell carcinoma arcc progress prior io therapi describ result patient treat nivolumab plus ipilimumab enrol track report patient histolog confirm clear cell arcc karnofski perform status life expect month previous progress io anti program death pd anti program death ligand pd l anti cytotox lymphocyt antigen ctla therapi elig previous treatment anti ctla therapi plus anti pd pd l therapi preclud elig enrol nivolumab plus ipilimumab arm patient treat nivolumab mgkg plus ipilimumab mgkg everi week four dose follow nivolumab mg everi week year progress toxic protocol specifi discontinu primari outcom measur object respons rate orr durat respons dor progress free surviv pfs rate week secondari outcom safeti toler year overal surviv os tertiaryexploratori endpoint overal patient includ median follow month orr ci eight patient achiev partial respons stabl diseas achiev patient progress diseas median dor rang month pfs rate week median os ci reach month grade immun mediat advers event report seven patient treatment relat death report patient arcc treat nivolumab plus ipilimumab may deriv durabl clinic benefit progress previous io therapi includ heavili pretreat patient manag safeti profil consist previous publish safeti outcom outcom contribut knowledg optim sequenc io therapi patient arcc high unmet need

D000971;D002292;D007680

T061;T191

36,328,375

transit pediatr adult care type diabet mellitus longitudin analysi age transfer gap care adolesc young adult aya type diabet td risk suboptim glycem control high acut care util littl known optim age transfer peopl td adult care time gap complet pediatr care begin adult endocrinolog care

D003922;D060305

T047;T058

36,328,372

effect oral antimicrobi prophylaxi surgic site infect elect colorect surgeri multicentr randomis doubl blind placebo control trial investig whether oral antimicrobi prophylaxi adjunct intraven antibiot prophylaxi reduc surgic site infect elect colorect surgeri

D003107;D009950;D000890

T121;T091;T109

36,328,364

complet ophthalmoplegia diagnos tolosa hunt syndrom interv mri tolosa hunt syndrom rare caus pain ophthalmoplegia common present retro orbit pain eye motor nerv palsi often affect singl eye condit characteris idiopath process caus granulomat inflamm cavern sinus affect one multipl cranial nerv pass therein mechan under inflamm well understood patient observ respond steroid flare present uniqu case multidisciplinari team diagnos tolosa hunt syndrom despit non specif mri find cavern sinus day follow initi normal mri

D020333;D009886;D002426

T033;T184;T047;T030

36,328,362

infant loey dietz syndrom treat febril status epilepticus covid infect first report case febril status epilepticus focal seizur patient loey dietz syndrom review literatur loey dietz syndrom lds rare autosom domin multisystem disord caus mutat transform growth factor receptor mutat smad tgfb recent reportedld characteris triad arteri tortuos hypertelor bifid uvula cleft palat among cardiovascular craniofaci orthopaed manifest patient lds show clinic genet variabl signific risk reduc life expect due widespread arteri involv aortic root dilat aneurysm aggress vascular cours thus earli genet test warrant clinic sign histori suggest potenti catastroph disorderld predispos patient aortic aneurysm earli death due vascular malform neurolog emerg seizur febril status epilepticus reportedfebril status epilepticus common neurolog emerg childhood neurolog manifest covid paediatr popul well describ medic literatureto best knowledg first report case febril status epilepticus covid infect infant lds patient focal epileptiform activ eman left posterior hemispher evolv electrograph seizur video eeg patient heighten risk epilepsi futur occurr consist diagnosi focal epilepsi neurolog complic epilepsi status epilepticus patient lds never report beforea brief review literatur also given

D055947;D000086382;D013226

T047;T067

36,328,361

float mural thrombus ascend aorta caus multiorgan infarct man sudden onset left side subcost pain diagnos splenic infarct thoracoabdomin ct contrast enhanc also reveal mural thrombus thoracoabdomin aorta rais possibl aortic dissect electrocardiograph find normal transthorac echocardiographi detect thrombus heart antihypertens medic administ admiss anticoagul therapi start develop left renal infarct occlus superior mesenter arteri nevertheless subsequ sustain acut cerebr infarct transoesophag echocardiographi reveal abnorm float structur ascend aorta surgic remov final diagnos organis thrombus although caus multiorgan infarct cardiogen float mural thrombus also caus anticoagul therapi may necessari patient recur sever embol even aortic dissect complet rule

D001018;D013927;D013923;D009203;D006331;D000784

T047;T046

36,328,355

synthet klhl ligand valid cul klhl potent e ligas target protein degrad target protein degrad tpd risen promis therapeut modal leverag catalyt natur ubiquitin proteasom enzymat machineri tpd exhibit higher potenc elimin diseas caus target protein oncogen transcript factor may otherwis difficult abrog convent inhibitor howev challeng remain current near degrad engag cul crbn cul vhl e ligas target ubiquitin immedi efficaci evid narrow e ligas option make tpd vulner potenti drug resist addit e ligas show differenti tissu express intrins limit access vari type diseas relev target success tpd close associ abil e ligas effici polyubiquitin target interest long term outlook tpd drug develop depend whether e ligas cul crbn cul vhl access target interest overcom potenti caveat broad collect action e ligas requir design macrocycl degrad engag cul klhl target bet protein valid cul klhl e ligas system suitabl tpd work thus contribut expans usabl e ligas potenti drug develop

D044767;D048868

T123;T126;T116

36,328,060

optoacoust tone generat nanosecond laser puls cover entir human hear rang aim work generat defin tone cover human hear rang aqueous media later applic middl inner ear implant experi investig characterist singl laser puls puls train differ laser repetit rate nanosecond laser puls focus aqueous media small volum frequenc generat tone limit spectral properti singl acoust puls depend medium tone fundament frequenc khz generat use laser puls focus water replac water gel tone hz khz could produc generat tone low frequenc rang possibl laser puls train puls densiti modul puls pattern appli gel enabl generat tone hz khz consequ combin differ puls pattern differ frequenc rang allow generat optoacoust tone hz khz gel thus cover complet rang human hear optoacoust generat tone

D006309;D000162

T039;T070

36,328,059

novel weight auxiliari set match pursuit method glioma cerenkov luminesc tomographi reconstruct cerenkov luminesc tomographi clt promis three dimension imag technolog activ investig preclin studi howev ill posed invers problem clt reconstruct reconstruct perform still satisfactori broad biomed applic studi novel weight auxiliari set match pursuit wasmp method explor enhanc accuraci clt reconstruct numer simul vivo imag studi use tumor bear mice model conduct evalu perform wasmp method result experi prove wasmp method achiev superior reconstruct perform approach term posit accuraci shape recoveri demonstr atom select strategi propos studi posit effect improv accuraci atom propos wasmp improv accuraci clt reconstruct biomed applic

D041622;D005910

T060;T191

36,328,058

tail artifact remov three dimension optic coher tomographi angiographi common part extract method optic coher tomographi angiographi octa blood vessel tail artifact tail superfici vessel shadow under deep vascular imag make difficult reconstruct three dimension imag vessel structur provid much inform two dimension imag import develop method remov artifact letter introduc imag process techniqu base common part extract remov artifact help subtract oper erod oper method reconstruct imag vascular network extract common part adjac b scan octa imag vessel palm use sampl experiment demonstr techniqu imag see interest phenomenon end blood vessel close surfac skin point toward surfac

D041623;D016477

T060;T068

36,328,055

digniti termin ill confront loss digniti suffer end life act digniti orient way usual abstract idea digniti fundament strengthen digniti focus deficit orient way sens digniti threaten look concept digniti health care system done two angl first direct gaze abus violat digniti right becom outrag moreov gain collect experi digniti violat covid pandem continu experi second focus enhanc digniti dignifi digniti orient aspir peopl work health care system follow articl intent devot second view open possibl digniti strengthen care health care system draw substanti research intervent develop harvey chochinov research team canada articl offer overview theoret foundat food thought self reflect action aid practic applic

D000078682;D000086382

T067;T055;T054;T047;T041

36,328,053

peri oper anaphylaxi antiqu custom news toward culprit periop anaphylaxi occur surgic procedur recent pathophysiolog anaphylact reaction via mast cell relat g protein und complement activ pseudo allergi ad old ige mediat etiolog new culprit anaphylact reaction chlorhexidin gelatin hemostypticum blue surgic dye mark situs biphas anaphylact reaction kept mind meantim propofol use allow egg soybean allerg patient

D000707;D005512;D015742

T121;T047;T046;T109

36,328,042

elect surgeri system strengthen develop measur valid surgic prepared index across hospit countri lancet commiss global surgeri identifi surgeri anaesthesia indispens part holist health care system howev covid expos fragil plan surgic servic around world also neglect pandem recoveri plan studi aim develop valid novel index support local elect surgic system strengthen address grow backlog

D058873;D000086382

T047;T067

36,328,040

addit isatuximab lenalidomid bortezomib dexamethason induct therapi newli diagnos transplant elig patient multipl myeloma gmmg hd part open label multicentr randomis activ control phase trial anti cd monoclon antibodi consist shown increas efficaci ad standard care patient multipl myeloma aim assess efficaci isatuximab addit lenalidomid bortezomib dexamethason patient newli diagnos transplant elig multipl myeloma

D009101

T191

36,328,025

acceler integr china global develop innov anticanc drug aim polici review compar china overal synchron particip clinic trial innov anticanc drug usa eu japan south korea assess chang particip rate trend five region relev data top intern pharmaceut compani systemat collect trialtrov pharmaproject databas among trial new anticanc drug identifi china involv trial drug triall particip rate signific lower south korea trial drug japan trial drug eu trial drug usa trial drug p similar result found synchron particip rate defin proport drug trial highest develop stage intern test drug rang china usa china particip rate earli phase trial synchron trial even lower stark contrast usa earli phase trial synchron trial fastest grow annual rate particip trial observ china follow south korea japan chang detect usa eu polici review show chines particip clinic develop innov cancer drug intern pharmaceut compani increas past decad obvious gap persist comparison usa eu japan south korea especi synchron particip earli particip rate

D000970

T121;T109

36,328,024

explor link cancer polici cancer surviv comparison intern cancer benchmark partnership countri cancer polici differ might help explain intern variat cancer surviv empir evid scarc review cancer polici intern cancer benchmark partnership jurisdict seven countri exploratori analys link index cancer polici consist time monitor implement mechan surviv seven cancer subset ten jurisdict ten jurisdict structur place overse deliv cancer control polici publish least one major cancer plan cancer plan explicit budget implement mandat extern evalu cancer polici consist posit correl improv surviv time six seven cancer site jurisdict score highest polici consist larg improv surviv site analysi provid import first step systemat captur evalu inher complex polici process find help guid polici maker seek approach framework improv cancer servic ultim cancer outcom

D019985;D009369

T081;T191

36,328,023

progress remain challeng cancer control gulf cooper council cancer grow global health care problem especi resourc countri cancer preval gulf cooper council gcc countri project increas potenti lead major burden economi polici maker gcc countri invest develop nation cancer control strategi address current futur burden cancer differ initi polici prevent earli detect manag cancer strategi includ capac build health educ global partnership strengthen health care system aim review highlight status cancer control programm gcc countri describ achiev date identifi gap recommend lower burden cancer gulf region futur translat arab translat abstract see supplementari materi section

D003695;D009369

T058;T191;T093

36,327,988

manag cylindr batteri ingest present femal present emerg depart follow ingest unknown number cylindr batteri diagnosi abdomin x ray confirm presenc multipl batteri locat throughout abdomen treatment trial conserv manag pursu five aa batteri success pass per rectum serial x ray three week reveal major batteri fail pass decis made perform laparotomi cylindr batteri remov stomach small gastrotomi four batteri locat colon milk rectum remov via transan rout discuss use daili clinic exam week plain film abdomen conserv manag possibl small number batteri ingest make stomach howev potenti cylindr batteri result acut surgic emerg underestim

D005547

T020;T037;T072

36,327,987

associ shift work normal weight obes communiti dwell adult shift work associ obes metabol syndrom howev associ normal weight popul remain unclear studi aim investig whether shift work associ normal weight obes nwo

D057187;D000073577

T056;T057

36,327,985

updat preoper parathyroid local primari hyperparathyroid parathyroidectomi treatment choic primari hyperparathyroid clinic criteria met although bilater neck explor tradit standard method surgeri minim invas parathyroidectomi mip focus parathyroidectomi wide accept compar curat outcom success mip accur preoper local parathyroid lesion essenti howev consensus exist optim approach local current ultrasonographi technetium sestamibi singl photon emiss comput tomographycomput tomographi wide accept case howev exact local alway achiev especi case multiglandular diseas ectop gland recurr diseas normocalcem primari hyperparathyroid therefor new modal preoper local develop evalu positron emiss tomographycomput tomographi parathyroid venous sampl demonstr improv sensit accuraci anatom function inform obtain combin method approach advantag disadvantag local studi deliber chosen base patient clinic profil cost radiat exposur avail experienc expert review summar various method local hyperfunct parathyroid tissu primari hyperparathyroid

D049950;D010282

T047;T191

36,327,984

updat paget diseas bone paget diseas bone preval bone diseas character disorgan bone remodel howev compar uncommon east asian countri includ china japan korea exact caus still remain unknown genet suscept individu environment trigger paramyxovir infect like caus diseas increas osteoclast activ result increas bone resorpt attract osteoblast generat new bone matrix fast bone resorpt format lead develop disorgan bone tissu increas serum alkalin phosphatas uniqu radiograph lesion may serv diagnost indic common symptom includ bone pain bow long bone enlarg skull hear loss diagnosi frequent confirm radiograph nuclear scintigraphi bone bisphosphon zoledron acid pamidron effect treatment moreov biochem monitor superior symptom recurr indic articl discuss updat paget diseas bone clinic case

D010001;D001862

T047;T042

36,327,969

caplacizumab use ttp case unrespons convent therapi introduct thrombot thrombocytopen purpura ttp rare life threaten disord caus sever reduc activ adamt caus platelet adhes format small vessel platelet rich thrombi thrombocytopenia microangiopath haemolyt anaemia diagnosi year old femal present acut general petechi rash bruis fatigu blood reveal thrombocytopenia anaemia schistocyt plasmic score seven adamt lt treatment patient initi respond plasma exchang steroid thrombocytopenia recur day six treatment need addit immunosuppress drug caplacizumab conclus ttp case unrespons convent regimen repres challeng situat howev poor outcom could potenti avoid novel therapi like caplacizumab patient medic well toler platelet count normal two day introduct

D011697;D061905

T129;T047;T116

36,327,900

sympathet nervous system st centuri neuroimmun interact metabol homeostasi obes sympathet nervous system maintain metabol homeostasi orchestr activ organ pancrea liver white brown adipos tissu first render thoma willi contemporari techniqu visual trace function probe axon arbor within organ understand sympathet nervous system start grow beyond classic model present review outlin evolut find provid updat neuroanatom map sympathet innerv offer autonom framework neuroendocrin loop leptin action discuss role immun cell regul sympathet termin metabol highlight potenti anti obes therapeut approach emerg modern appreci sns neural network vis vis histor fear sympathomimet pharmacolog shift focus post pre synapt target final critic apprais field need go

D015213;D013564

T022;T023;T040

36,327,899

neuron regul b cell immun anticipatori immun postur brain may sens evalu modul interven oper immun system would otherwis function autonom defens pathogen antibodi mediat immun one arm adapt immun may achiev steril protect infect lymphoid organ dens innerv immun cell support antigen specif antibodi respons express receptor neurotransmitt glucocorticoid hormon subject collect regul neuroendocrin autonom nervous system emerg evid reveal brain spleen axi regul antigen specif b cell respons antibodi mediat immun articl provid synthesi studi pertin neuron regul b cell respons secondari lymphoid organ propos concept defens immun postur brain initi top reaction anticip potenti tissu injuri requir immun protect

D009490;D007107

T022

36,327,898

perivascular space role neuroinflamm uncontest perivascular space play critic role maintain homeostasi prime neuroinflamm howev despit centuri intens research perivascular space mani open question remain anatom compart surround blood vessel within cns goal comprehens review summar literatur perivascular space human neuroinflamm associ anim diseas model describ cell type take part morpholog function aspect perivascular space space visual base propos model cascad event occur neuroinflammatori patholog also discuss current knowledg gap limit avail evid improv understand perivascular space could advanc comprehens pathophysiolog neuroinflamm open new therapeut window neuroinflammatori diseas multipl sclerosi

D008279;D000090862

T060;T059;T033;T170;T047

36,327,897

microgli efferocytosi dive alzheim diseas gene pool genom wide associ studi function genom studi link specif cell type gene pathway alzheim diseas ad risk particular ad risk allel primarili affect abund structur thus activ gene express macrophag strong implic microglia brain resid macrophag etiolog ad gene converg pathway endocytosisphagocytosi cholesterol metabol immun respons critic role core macrophag function efferocytosi review pathway highlight relev gene identifi latest ad genet genom studi describ may contribut ad pathogenesi investig function impact ad associ variant gene microglia essenti elucid diseas risk mechan develop effect therapeut approach

D017628;D000544

T047;T025;T048

36,327,896

cns mononuclear phagocyt system health diseas cns resid macrophag includ parenchym microglia border associ macrophag bam contribut neuron develop health vascular tissu integr steadi state border patrol mononuclear phagocyt dendrit cell monocyt confer import immun function cns protect pathogen threat includ aberr cell growth brain malign even though learn much contribut lymphocyt cns patholog better understand differenti role tissu resid invad phagocyt slowli emerg perspect propos cns neuroinflammatori diseas tissu resid macrophag trms contribut clear debri resolut inflamm wherea blood born phagocyt driver immunopatholog discuss remain challeng resolv special mononuclear phagocyt popul drive suppress immun effector function therebi potenti dictat outcom autoimmun brain cancer

D012157;D001932

T022;T191

36,327,895

microglia state nomenclatur field crossroad microgli research advanc consider recent decad yet constrain roll seri dichotomi rest versus activ versus dualist classif good bad microglia inconsist wide repertoir microgli state function develop plastic age diseas elucid recent year new design continu aris attempt describ differ microgli state notabl defin use transcriptom proteom may easili lead mislead although unintent coupl categori function address issu assembl group multidisciplinari expert discuss current understand microgli state dynam concept import address microgli function provid conceptu framework recommend use microgli nomenclatur research review editor serv foundat futur white paper

D017628

T025

36,327,894

advanc vitro model microglia action central nervous system cns microglia carri multipl task relat brain develop mainten brain homeostasi function cns recent advanc vitro model system allow us perform detail specif analys microgli function cns develop human pluripot stem cell hpscs base cell cultur method particular advanc brain organoid model offer better platform dissect microgli function various context despit improv method still definit restrict understand drawback benefit ensur proper use primer review current develop regard vitro microgli product character use address fundament question microgli function healthi diseas state discuss potenti futur improv particular emphasi brain organoid model

D017628;D039904

T025

36,327,893

immunocept defin brain regul immun emerg understand homeostat neuroimmun interact requir develop relev terminolog neuroview koren roll defin immunocept brain bidirect monitor control immun propos physiolog trace store immun relat inform immunengram distribut brain memori cell resid peripher tissu

D001921;D015213

T022;T023;T040

36,327,892

jonathan kipni interview neuron joni kipni discuss format academ year subsequ discoveri mening lymphat enthusiast prospect therapeut develop neuroimmunolog aris focus brain border

D008208;D008578

T022;T023

36,327,891

gloria choi interview neuron gloria choi give us overview work character neural circuit behavior affect immun challeng various context also learn uniqu perspect marri two disciplin neurosci immunolog

D000486;D009488;D009420

T022;T091

36,327,890

larri steinman larri steinman divid time neurolog clinic lab team help develop first antibodi therapi multipl sclerosi interview neuron talk famili upbring team strategi princip investig long trajectori translat medicin

D009103;D009462

T047;T091

36,327,889

frauk zipp frauk zipp clinician scientist expert multipl sclerosi neurolog disord interview neuron talk earli work neuroimmunolog lab research advanc understand interplay immun nervous system health diseas

D009103;D009422

T047

36,327,888

neuro immun interact spectacular forest special issu neuron present seri opinion review neuro immun interact recent insight profound nervous immun system affect bolster tran disciplinari collabor revolution neurosci immunolog like forest ecosystem organ thrive wither depend balanc compon highlight special issu small sampl ever grow list diseas influenc dysfunct neuro immun crosstalk rang multipl sclerosi brain cancer long covid alzheim

D000086382

T047;T067

36,327,641

preval oncogen human papillomavirus pregnant adolesc associ colpocytolog chang risk factor obstetr outcom author aim carri investig impact cervic oncogen human papillomavirus hpv detect pregnant adolesc clarifi preval risk factor consid import lack data topic brazil

D052685;D030361;D002583

T005;T191;T047

36,327,640

supplement l carnitin septic shock patient systemat review meta analysi sepsi septic shock sever difficult treat condit high lethal interest identifi new adjunct therapi effect reduc mortal context l carnitin investig trial potenti benefici drug therefor aim systemat review assess clinic evid support use l carnitin septic shock patient reduc risk mortal object review evalu effect l carnitin compar placebo usual care uc mortal rate hospit adult septic shock patient

D012772;D018805

T047;T046

36,327,639

variabl isokinet ankl strength differ healthi older men women elder weak lower limb muscl impair function task perform

D000842;D000843

T029;T030

36,327,584

contribut filtrat photocatalysi dom remov foul mechan situ uv led photocatalyt ceram membran process use ceram membran ultraviolet light emit diod uv led advanc applic photocatalyt membran water treatment systemat evalu contribut filtrat photocatalysi dissolv organ matter dom remov foul mechan situ uv led photocatalyt ceram membran filtrat result show physic reject primarili led remov kda molecul photocatalysi increas remov kda molecul caus small size microbi humic like protein like materi permeat situ uv led photocatalysi excel effect membran foul mitig regardless dom sourc domin foul mechan chang partial blockag gel layer format increas ca concentr chang uv treatment correl analysi reveal remov kda molecul contribut mitig revers irrevers foul resist small molecul major caus irrevers foul resist remov kda terrestri humic acid like contribut pore blockag mechan synthet water remov kda protein like materi close correl pore blockag mechan real water trihalomethan thms haloacet acid haa format potenti fp signific reduc photocatalyt ceram membran process precursor nitrogen disinfect product n dbps high toxic remov filtrat photocatalysi deserv attent membran reject made higher contribut better dbpfp control photocatalysi studi provid novel insight impact uv led dom remov dbpfp control foul mitig promot develop photocatalyt ceram membran filtrat

D008567;D018508

T074;T052;T057

36,327,550

effect age limb centr pressur coordin stand balanc evid reactiv control challeng among older adult interlimb tempor synchroni spatial symmetri centr pressur cop displac may vital contributor stand balanc control previous work among stroke survivor low frequenc cop displac hz contrast attribut correct balanc respons intern perturb present studi extend work explor age relat alter stabil control process stand balanc combin cop displac limb cop net addit individu limb cop timeseri calcul synchron forc platform data obtain younger adult older adult trial quiet stand discret wavelet transform use decompos anteroposterior mediolater cop net addit individu limb timeseri low frequenc high frequenc bandwidth root mean squar rms amplitud high low frequenc cop net displac calcul cross correl coeffici use assess extent limb tempor synchron ratio individu limb rms amplitud use assess limb spatial symmetri within high low frequenc bandwidth observ greater high frequenc anteroposterior cop net displac among older adult without age relat differ lower frequenc bandwidth mediolater direct older adult exhibit greater high frequenc anteroposterior limb synchron without age relat differ low frequenc bandwidth among spatial symmetri variabl present age relat alter cop net could repres conserv strategi ensur stabil wherebi age relat challeng stabil mainten stand offset greater demand stabil control increas high frequenc limb tempor synchron among older adult may suggest loss adapt balanc correct respons stand

D011187;D020521

T033;T047

36,327,460

dynam interplay thionin dna carbon ion irradi real time first principl studi understand interact deoxyribonucl acid dna photosensit ion irradi benefit develop aptasensor dna biosensor cancer diagnosi use real time time depend densiti function theori simul high energi c ion pass dna poli dg poli dc sequenc embed thionin diamino phenothiazinium th compar electron stop power esp evolut structur charg absorpt spectrum th insert lead increas space charg densiti larger electron de excit larger esp speed correspond maximum esp almost c ion pass th dna structur th slight chang still exist noncoval interact th dna absorpt coeffici depend electron occupi state th ion pass result indic low radiat dose th still dna detector although respons wavelength intens slight chang provid theoret refer improv possibl applic phenothiazin dye dna biosensor ion irradi

D010640;D015374

T121;T059;T075;T109

36,327,447

practic strategi health equiti research enhanc analyt rigor generat meaning insight qualit data research public health practition increas need leverag divers methodolog approach health equiti research lead innov assess health inequ develop intervent decreas health inequ one well suit approach use robust qualit method alon combin quantit method health equiti research employ qualit method studi design addit guidanc need conduct robust rigor qualit data analys share step analyt strategi health equiti research practition particular limit train qualit data analysi use effect execut qualit analysi inform health equiti driven effort strategi guid less experienc qualit methodolog employ pragmat approach analysi sound reason produc meaning insight use inform effort advanc health equiti communiti greatest need

D000069576

T080

36,327,444

long term clinic clerkship improv medic student attitud toward team collabor examin relat factor associ medic student attitud toward team collabor

D002982;D013337

T065;T097

36,327,438

inflammatori bowel diseas associ colorect cancer epidemiolog outcom english popul base studi patient inflammatori bowel diseas ibd colon increas risk colorect cancer crc studi investig epidemiolog ibd crc outcom

D003093;D015179;D015212;D003424;D002761

T047;T191

36,327,437

longitudin associ risk factor hepatocellular carcinoma patient cure hepat c virus infect limit data effect evolut risk factor hepatocellular carcinoma hcc patient virolog cure hepat c virus hcv infect

D006528;D008113;D019698;D006526

T047;T191

36,327,436

random dose find proof concept studi berberin ursodeoxychol patient primari scleros cholang primari scleros cholang psc fibroinflammatori diseas bile duct lead cirrhosi hepat decompens approv pharmaceut therapi psc berberin ursodeoxychol htd ionic salt berberin ursodeoxychol acid pleiotrop mechan action

D015209;D001599

T121;T047;T109

36,327,435

berberin ursodeoxychol treatment primari scleros cholang search elus pharmacolog holi grail need continu effect pharmacolog treatment primari scleros cholang psc remain elus ursodeoxychol acid udca known improv liver biochemistri specif serum alkalin phosphatas patient psc shown favour alter natur histori similar mani immunomodulatori medic studi treatment psc none demonstr unequivoc benefit issu journal pilot studi ursodeoxychol berberin salt vs placebo report although improv serum alkalin phosphatas report without control arm udca monotherapi possibl determin whether studi drug benefici udca studi psc therapeut arena need

D015209;D001599

T121;T047;T109

36,327,434

gastroesophag reflux diseas great screen criterion time move strategi control burden esophag adenocarcinoma gastroesophag reflux diseas gerd key pathogenesi barrett esophagus esophag adenocarcinoma eac endoscop screen select individu gerd symptom barrett esophagus eac recommend great major patient eac never undergon prior screen despit million esophagogastroduodenoscopi egd perform annual unit state among individu gerd symptom like due conflat among provid regard diagnost egd refractori symptom screen egd altern approach need de emphas gerd avoid confus increas uptak appropri screen

D001471;D004938;D005764;D000230

T047;T191

36,327,433

continu medic educ question novemb articl titl longitudin associ risk factor hepatocellular carcinoma patient cure hepat c virus infect

D008113;D006528;D006526

T047;T191

36,327,432

continu medic educ question novemb articl titl qualiti indic capsul endoscopi deep enteroscopi

D004502;D053704

T065;T060

36,327,419

preval metal level refer valu municip affect collaps mine tail dam brumadinho health project describ preval level arsenic cadmium mercuri lead manganes refer valu rv popul brumadinho ruptur mine tail dam verifi factor associ level

D002104;D008628

T131;T196

36,327,418

laboratori profil mine dam breach brumadinho health project result evalu chang select laboratori test popul includ brumadinho health project accord exposur dam failur

D002097

T129;T116

36,327,417

use psychotrop drug popul area affect tail dam ruptur brumadinho health project describ consumpt psychotrop drug adult popul resid brumadinho mina gerai vale dam collaps occur

D014151

T121;T039

36,327,416

preval psychiatr symptom associ factor adult popul area affect tail dam ruptur brumadinho health project examin preval psychiatr symptom associ factor adult popul brumadinho mg dam collaps

D013313

T048

36,327,415

factor associ paid work dam failur brumadinho health project analyz factor associ paid work dam failur base geograph strata among men women resid brumadinho mina gerai

D004651

T033;T098;T080

36,327,414

chronic respiratori diseas respiratori symptom mine dam ruptur brumadinho health project identifi factor associ asthma chronic obstruct pulmonari diseas copd respiratori symptom brumadinho state mina gerai brazil dam ruptur

D029424;D001249

T047

36,327,413

food consumpt brumadinho health project particip analyz food consumpt pattern resid brumadinho mina gerai brazil accord sociodemograph characterist neighborhood area resid

D014675;D005638

T168;T002

36,327,412

brumadinho health project food nutrit insecur versus socioeconom status dimens food system dam ruptur describ situat food insecur famili accord socioeconom characterist dimens food system brumadinho state mina gerai brazil dam ruptur crrego feijo mine

D005523;D009752

T081;T033

36,327,411

sociodemograph residenti factor associ multimorb result brumadinho health project evalu preval multimorbid sociodemograph residenti factor associ condit among adult live brumadinho mina gerai

D000076322

T078

36,327,410

healthcar access util qualiti disast result brumadinho health project januari dam crrego feijo mine suffer catastroph failur kill peopl caus extens damag unknown exposur disast might affect healthcar util

D001786;D004190

T067;T109

36,327,409

mine dam disast system risk brazil record two serious disast involv mine dam st centuri purpos articl offer understand disast system risk involv global nation process relat social determin materi complex system dam distribut throughout countri intrins risk occur result set impact potenti damag immedi effect combin secondari tertiari impact trigger chain reaction promot risk factor heterogen complex occurr approach event point view system risk allow broader understand singular disast multipl exposur risk diseas process well structur characterist social polit process dynam econom factor reproduc multipl territori common pattern disast effect conclud promot popul health sustain territori guid organ product process opposit extern human environment social cost mine disast

D004190

T067

36,327,408

protocol longitudin studi child health brumadinho mg bruminha project present research protocol describ preliminari result bruminha project

D000067576

T078;T058

36,327,407

brumadinho health project methodolog aspect epidemiolog profil particip cohort baselin present methodolog aspect brumadinho health project describ epidemiolog profil particip baselin cohort

D015331

T062;T081

36,327,405

nlrp inflammasom inhibitor mcc reduc damag pancreat intestin barrier function mice acut pancreat abnorm activ nod like receptor protein nlrp inflammasom lead occurr progress acut pancreat studi investig protect effect mcc pancreat mice

D058847;D000071199;D010195

T123;T047;T046;T116

36,327,404

jatrorrhizin reduc myocardi infarct induc apoptosi fibrosi inhibit p tgf smad pathway mice explor mechan jatrorrhizin apoptosi fibrosi induc myocardi infarct mi anim model

D009203;D053773

T123;T047;T121;T116

36,327,403

tanshinon iia amelior myocardi ischemiareperfus injuri rat regul nlrp inflammasom activ th cell differenti tanshinon iia well known lipophil activ constitu refin tradit chines medicin danshen previous demonstr possess various biolog properti includ anti inflammatori antioxid promot angiogenesi effect howev mechan tanshinon iia myocardi ischemia reperfus injuri miri remain unclear studi investig effect tanshinon iia miri

D015428

T046

36,327,401

comprehens model implement agricultur land level consolid plan abu fazel region ahvaz shown land fragment negat impact effici farm therefor expert recommend land consolid process logic workabl solut solv problem complic caus land fragment land level consolid process land reform chang construct agricultur land lead rural develop reform farm manag howev singl plan appli differ region even though might countri henc vital investig multipl factor certain region devis perfect consolid plan present studi survey exploratori research conduct provid comprehens model implement plan level consolid agricultur land abu fazel region ahvaz iran research appli field research use librari field method collect requir data studi popul abu fazel northeast ahvaz zargan region result studi show cultur social econom polici make educ agricultur manageri factor effect particip farmer level consolid agricultur land studi area p also strong posit relationship factor farmer particip level consolid agricultur land p among factor observ polici main factor policymak play effect role land consolid macro develop one hand agricultur rural develop accur assess interact effect land consolid relat factor along effect process evolut agronom system

D000383;D003247

T078;T090;T069;T081;T064

36,327,400

temperatur variat nest paleosuchus palpebrosus crocodylia alligatorida near southern edg speci rang brazil monitor temperatur seven paleosuchus palpebrosus nest found bank stream surround brazilian pantan near southern limit speci distribut mean temperatur nest day incub presum period sex determin vari c nest temperatur c higher air temperatur presum due metabol heat decay materi within nest air temperatur explain varianc egg chamber temperatur estim incub period nest egg hatch day mean sd day though probabl slight overestim egg may hatch period inspect nest signific relationship mean temperatur incub period r p

D000489

T014

36,327,399

method applic salicyl acid attenu salt stress cherri tomato salt stress caus excess salt present irrig water one biggest barrier agricultur product especi semi arid region thus use substanc salicyl acid minim deleteri effect salin plant altern ensur satisfactori product context object studi evalu effect differ method applic salicyl acid growth product water use effici cherri tomato plant salt stress studi conduct greenhous use entisol soil sandi loam textur treatment distribut complet random design factori arrang correspond two level electr conduct irrig water ecw ds four method applic salicyl acid control without applic sa via spray via irrig via spray irrig five replic one plant per plot salicyl acid concentr use differ method mm applic salicyl acid via foliar spray increas growth product water use effici cherri tomato plant salt stress induc electr conduct ds attenu foliar applic salicyl acid use water ds associ applic salicyl acid via irrig water intensifi advers effect salin cherri tomato plant

D018551

T168;T002

36,327,398

use aerob treadmil exercis nerv regener sciatic nerv injuri spontan hypertens rat various postop protocol propos improv outcom acceler nerv regener recent use physic exercis post surgic neurorraphi procedur shown good result start earli experiment investig hypothesi post oper exercis speed result improv clinic morpholog paramet

D009416;D059348;D020426;D010805

T042;T037;T043;T047;T038

36,327,397

anatom descript extratempor facial nerv high definit system microsurg studi rat describ microsurg anatom aspect extratempor facial nerv wistar rat high definit video system

D005154;D004210

T061;T023

36,327,396

incision hernia repair rat descript sublay techniqu videomagnif system describ techniqu sublay correct incision hernia wistar rat videomagnif system

D000069290;D006555

T046;T190

36,327,395

outbreak toxoplasmosi associ muscular lesion finish pig caus atyp toxoplasma gondii genotyp toxoplasma gondii infect usual asymptomat pig acut clinic diseas rare host studi aim determin patholog molecular aspect outbreak fatal system toxoplasmosi finish pig brazil outbreak occur commerci finish pig farm state santa catarina southern brazil farm pig mortal rate outbreak pig fever anorexia apathi locomotor deficit seven pig necropsi gross find includ multifoc coalesc pale area skelet muscl lymphadenomegali hepatosplenomegali non colaps lung histolog find includ granulomat lymphaden hepat spleniti necrot myositi lymphoplasmacyt interstiti pneumonia lung liver lesion occasion accompani gondii parasit structur posit immunolabel gondii tachyzoit encyst bradyzoit detect examin pig pcr rflp marker microsatellit analysi marker identifi non archetyp genotyp pig first report system toxoplasmosi pig muscl lesion addit show divers diseas caus gondii genotyp circul anim brazil

D014122;D014124;D013553

T047;T204

36,327,393

auditori process intervent program school age children develop content valid studi aim develop content valid auditori process intervent program school age european portugues speak children auditori process disord

D001307;D001308

T041;T048

36,327,391

cdc clinic practic guidelin prescrib opioid pain unit state guidelin provid recommend clinician provid pain care includ prescrib opioid outpati age year updat cdc guidelin prescrib opioid chronic pain unit state mmwr recomm rep rr includ recommend manag acut durat month pain recommend appli pain relat sickl cell diseas cancer patient receiv palliat end life care guidelin address follow four area determin whether initi opioid pain select opioid determin opioid dosag decid durat initi opioid prescript conduct follow assess risk address potenti harm opioid use cdc develop guidelin use grade recommend assess develop evalu grade framework recommend base systemat review scientif evid reflect consider benefit harm patient clinician valu prefer resourc alloc cdc obtain input board scientif counselor nation center injuri prevent control feder charter advisori committe public peer review cdc recommend person pain receiv appropri pain treatment care consider benefit risk treatment option context patient circumst recommend appli inflex standard care across patient popul clinic practic guidelin intend improv communic clinician patient benefit risk pain treatment includ opioid therapi improv effect safeti pain treatment mitig pain improv function qualiti life patient pain reduc risk associ opioid pain therapi includ opioid use disord overdos death

D059350;D009293

T184;T047;T048

36,327,381

preval distribut refract error among member us arm forc us coast guard calendar year estim preval myopia hyperopia astigmat activ compon us arm forc us coast guard respect preval spectacl correct activ compon us arm forc includ singl vision distanc multifoc eg bifoc singl vision read spectacl comparison preval spectacl correct us coast guard addit among us arm forc servic member receiv spectacl correct distanc vision servic member reserv compon militari academi cadet nation guard signific myopic near sighted activ compon coast guard p within activ compon air forc myopic marin corp follow close militari branch signific differ p signific myopic navi armi p navi myopic armi p us coast guard signific less myopic militari branch p

D008889;D012030;D006956;D001251;D009216

T047;T097

36,327,377

musculoskelet injuri us air forc special warfar train assess select fiscal year incept special warfar train wing fiscal year male enlist candid attempt least assess select self elimin ie quit candid averag year age candid first attempt individu experienc musculoskelet msk injuri among injuri frequent type nonspecif n common anatom region injuri lower extrem n includ multivari model older age slower run time initi fit test prior nonspecif injuri associ injuri specif lower extrem msk injuri

D008889;D009140

T047;T097

36,327,353

complex disloc metacarpophalang joint index finger child case report author report complex metacarpophalang joint disloc year old adolesc boy multipl fail close reduct manipul unsuccess open procedur patient underw anoth surgic procedur volar approach joint reduc along volar plate repair function outcom year follow excel

D004204;D019651

T061;T037

36,327,350

reifi racism medicin master health racial scienc slaveri us medic school christoph e willoughbi univers north carolina press pp fals belief racial differ long histori physician train program

D063505;D063947

T054

36,327,349

solv brain circuit function dysfunct comput model optogenet fmri construct model brain function enabl understand whole brain circuit mechan under neurolog diseas use predict outcom therapeut intervent patholog neurolog diseas observ spatial spread mechan associ circuit brain function review discuss approach use date futur direct explor answer question combin optogenet function magnet reson imag fmri comput model cell type specif larg scale brain circuit function dysfunct begin quantit parameter envis develop pave path futur therapeut develop base system engin approach aim direct restor brain function

D062308;D009422

T063;T047